ASX Announcement

20 November 2026

ASX Limited

Market Announcements Office

39 Martin Place

SYDNEY NSW 2000

Update on sale of Agilex Biolabs to Novotech

Healius Limited (**Healius**) (ASX: HLS) provides an update on the sale of Agilex Biolabs Pty Ltd (**Agilex**) to Novotech, announced on 25 September 2026.

On 18 November 2026, the Australian Competition and Consumer Commission (**ACCC**) issued its Phase 1 determination that the proposed acquisition may be put into effect.

Completion of the transaction remains subject to completion of the applicable 14-calendar-day statutory period following the ACCC determination and receipt of Foreign Investment Review Board (**FIRB**) approval.

Healius will provide a further update when these remaining regulatory conditions have been satisfied.

This announcement has been authorised for release by the Managing Director and CEO of Healius Limited.

For further information please contact:

Investor Enquiries

Andrew Thomson
Chief Financial Officer
Healius Limited
investor.relations@healius.com.au

Media Enquiries

Susannah Rands
Head of Communications
Healius Limited
media@healius.com.au

About Healius Limited

For over 30 years Healius has been one of Australia's leading healthcare companies, committed to supporting quality, affordable and accessible healthcare for all Australians. Through its unique footprint of centres and its 8,500+ employees, Healius provides Australia-wide specialty pathology services to consumers and their referring practitioners.

Forward looking statements

This announcement may contain forward-looking statements, including statements about expectations, intentions or future outcomes. These statements are subject to risks, uncertainties and assumptions, many beyond Healius' control, and actual results may differ materially. Healius gives no assurance that any forward-looking statement will be achieved and investors should not place undue reliance on them.